Study on the Molecular Mechanism of Stephania Terandra in the Therapy for Hypertension Based on Inte-grated Pharmacology Platform / 中国药师
China Pharmacist
; (12): 1716-1720, 2018.
Article
en Zh
| WPRIM
| ID: wpr-705689
Biblioteca responsable:
WPRO
ABSTRACT
Objective:
To explore the potential genetic target of Stephania terandra in the therapy for hypertension based on inte-grated pharmacology platform to study the molecular mechanism of Chinese medicines in treating hypertension.Methods:
Using the functional prediction modules of integrated pharmacology platform and the functional modules of network construction, the component-target network of Stephania terandra was calculated, and the target network of anti-hypertension was further calculated, and the target molecules related to hypertension were explored.Results:
A total of 198 targets related to hypertension were obtained from the hyper-tension prevention. Among them, there were 59 potential action nodes and 20 known action nodes. The nodes with direct action were type-2 angiotensin Ⅱ receptor ( AGTR2), type-1 angiotensin Ⅱ receptor ( AGTR1), prostacyclin receptor ( PTGIR), solute carrier family 12 member 3 (SLC12A3) and endothelin-1 (EDN1). The GO enrichment and KEGG pathway enrichment of Stephania terandra chemical components showed a close correlation with hypertension, and the molecular mechanism of the target was clear.Conclusion:
Through the integration of pharmacology platform, the targets of Stephania terandra-disease are deeply explored, and its potential mo-lecular mechanism as well as potential factors is studied.
Texto completo:
1
Índice:
WPRIM
Tipo de estudio:
Prognostic_studies
Idioma:
Zh
Revista:
China Pharmacist
Año:
2018
Tipo del documento:
Article